Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard Growth Index Fund ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.78 (market cap $78.67M), while Vanguard Growth Index Fund ETF trades at $89.15. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | VUG | |
|---|---|---|
Market Cap | $78.67M | — |
Sector | Health | Sector/Thematic |
52-Week High | $2.87 | $90.29 |
52-Week Low | $0.66 | $70.00 |
Enterprise Value | $50.00M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Vanguard Growth ETF (VUG) trades at $88.87, down 0.35% today, with a bullish technical outlook supported by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing positions by over 500% in Q2 2026. Technical indicators show overbought RSI levels but strong trend momentum with ADX readings above 30.
VUG offers exposure to large-cap growth stocks with historical outperformance versus the S&P 500. Risks include growth stock volatility and concentration in technology sectors. The ETF remains attractive for long-term investors seeking growth exposure, though current overbought conditions suggest potential for near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
